Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for co…
The bill amends the Controlled Substances Act to permit a telehealth medical evaluation when prescribing FDA‑approved Schedule III, IV, or V controlled substances for treating substance use disorder. It retains reference to an in‑person medical evaluation requirement while adding a definition of "telehealth evaluation" that allows two‑way audio‑only or audio/video communications under applicable Federal and State law.
Access versus safety: expanded access vs. diversion concerns
Narrow health access reform with low fiscal impact likely attracts bipartisan support, though oversight concerns about diversion may prompt scrutiny.
The bill amends the Controlled Substances Act to permit a telehealth medical evaluation when prescribing FDA‑approved Schedule III, IV, or V controlled substances for treating substance use disorder.
It retains reference to an in‑person medical evaluation requirement while adding a definition of "telehealth evaluation" that allows two‑way audio‑only or audio/video communications under applicable Federal and State law.
The telehealth evaluation must be conducted by a practitioner (not a pharmacist) located remotely or the treating practitioner.
Targeted, low‑cost reform with bipartisan appeal on access; countervailing safety, enforcement, and federal‑state concerns reduce passage odds.
How solid the drafting looks.
Access versus safety: expanded access vs. diversion concerns
These are examples from the analysis, not a ranked list of the most-affected groups.
Access versus safety: expanded access vs. diversion concerns
Likely to view the bill favorably as it reduces access barriers to addiction treatment and expands telehealth options.
They will emphasize potential public‑health gains from easier access to medications like buprenorphine and support audio‑only access for underserved populations.
Some caution will be voiced about ensuring equity, monitoring, and supports for patients.
Cautious support is likely: the bill expands access but raises legitimate safety and oversight questions.
Centrists will weigh public health benefits against diversion risks and seek clear federal‑state roles, funding for monitoring, and defined safeguards.
They will favor targeted guardrails rather than broad, unrestricted teleprescribing.
Likely skeptical or opposed due to concerns about loosening controls on controlled substances and potential diversion.
Conservatives will emphasize patient safety, law enforcement implications, and opposition to audio‑only prescribing without stricter verification.
They may accept limited telehealth under robust safeguards and enforcement.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Targeted, low‑cost reform with bipartisan appeal on access; countervailing safety, enforcement, and federal‑state concerns reduce passage odds.
The bill has not accumulated any surfaced votes yet.
Access versus safety: expanded access vs. diversion concerns
Targeted, low‑cost reform with bipartisan appeal on access; countervailing safety, enforcement, and federal‑state concerns reduce passage o…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for TREATS Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.